Henagliflozin
Pharmaceutical drug
- Rx in China
- (1R,2S,3S,4R,5R)-5-[4-Chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- 1623804-44-3
- 56832738
- DB11939
- 21P2M98388
Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2][3]
Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]
References
- ^ Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, et al. (August 2021). "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism. 23 (8): 1754–1764. doi:10.1111/dom.14389. PMID 33769656.
- ^ Wang G (17 February 2022). "Monthly Report: New Drug Approvals in China, January 2022". BaiPharm.
Henagliflozin Proline Tablets
- ^ "Henagliflozin - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
- ^ He X, Liu G, Chen X, Wang Y, Liu R, Wang C, et al. (July 2023). "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics. 45 (7): 655–661. doi:10.1016/j.clinthera.2023.06.002. PMID 37451912.
- v
- t
- e
Sodium-glucose transporter modulators
- Inhibitors: Phloretin
- Phlorizin
- T-1095
- T-1095A
- Inhibitors: Atigliflozin
- Bexagliflozin
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- Enavogliflozin
- Ertugliflozin
- Henagliflozin
- Ipragliflozin
- Janagliflozin
- Licogliflozin
- Luseogliflozin
- Mizagliflozin
- Phloretin
- Phlorizin
- Remogliflozin
- Sergliflozin
- T-1095
- T-1095A
- Tofogliflozin
- Velagliflozin
- Antisense oligonucleotides: ISIS-388626
- Inhibitors: Sotagliflozin
See also: Receptor/signaling modulators